Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30379% above fair value
$15.71−0.15 (-0.95%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
Personalis r&d expenses
Research and development expenses are spending on new products and technology.
Personalis's R&D Expenses for the twelve months ending Sep 30, 2026 was $60.02M, up 23.3% year over year. For fiscal 2025 it was $50.26M, up 2.8% from the year before. The highest annual figure on record is $64.91M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.26M | +2.8% |
| FY2024 | Dec 31, 2024 | $48.91M | -24.5% |
| FY2023 | Dec 31, 2023 | $64.78M | -0.2% |
| FY2022 | Dec 31, 2022 | $64.91M | +31.6% |
| FY2021 | Dec 31, 2021 | $49.31M | +72.6% |
| FY2020 | Dec 31, 2020 | $28.57M | +27.4% |
| FY2019 | Dec 31, 2019 | $22.42M | +56.7% |
| FY2018 | Dec 31, 2018 | $14.30M | +44.2% |
| FY2017 | Dec 31, 2017 | $9.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.07M | +32.1% |
| Q2 FY2026 | Jun 30, 2026 | $16.34M | +31.9% |
| Q1 FY2026 | Mar 31, 2026 | $14.54M | +15.0% |
| Q4 FY2025 | Dec 31, 2025 | $13.07M | +13.7% |
| Q3 FY2025 | Sep 30, 2025 | $12.17M | +4.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.38M | -4.4% |
| Q1 FY2025 | Mar 31, 2025 | $12.64M | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $11.49M | -15.6% |
| Q3 FY2024 | Sep 30, 2024 | $11.68M | -30.2% |
| Q2 FY2024 | Jun 30, 2024 | $12.96M | -27.4% |
| Q1 FY2024 | Mar 31, 2024 | $12.77M | -22.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.61M | -17.8% |
| Q3 FY2023 | Sep 30, 2023 | $16.74M | +11.9% |
| Q2 FY2023 | Jun 30, 2023 | $17.85M | +9.6% |
| Q1 FY2023 | Mar 31, 2023 | $16.57M | -3.1% |
| Q4 FY2022 | Dec 31, 2022 | $16.57M | +14.2% |
| Q3 FY2022 | Sep 30, 2022 | $14.96M | +9.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.29M | +39.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.10M | +80.1% |
| Q4 FY2021 | Dec 31, 2021 | $14.51M | +70.3% |
| Q3 FY2021 | Sep 30, 2021 | $13.62M | +89.3% |
| Q2 FY2021 | Jun 30, 2021 | $11.69M | +80.8% |
| Q1 FY2021 | Mar 31, 2021 | $9.50M | +48.6% |
| Q4 FY2020 | Dec 31, 2020 | $8.52M | +15.6% |
| Q3 FY2020 | Sep 30, 2020 | $7.19M | +35.6% |
| Q2 FY2020 | Jun 30, 2020 | $6.47M | +43.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.39M | +21.8% |
| Q4 FY2019 | Dec 31, 2019 | $7.37M | +72.2% |
| Q3 FY2019 | Sep 30, 2019 | $5.30M | +48.4% |
| Q2 FY2019 | Jun 30, 2019 | $4.50M | +28.5% |
| Q1 FY2019 | Mar 31, 2019 | $5.25M | – |
| Q4 FY2018 | Dec 31, 2018 | $4.28M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.57M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.50M | – |
See a number that looks wrong?